Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Tuesday, April 15, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has received Fast Track Designation from the U.S. FDA for its innovative gene editing therapy, PBGENE-HBV, aimed at treating chronic Hepatitis B. This designation is significant as it may expedite the development and review process due to the therapy's potential to address a major health concern. The company utilizes its proprietary ARCUS platform for this advancement.
Price reaction · baseline $4.46 (2025-04-14 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+23.8%
day 1
+12.3%
day 3
+15%

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA Fast Track Designation granted for PBGENE-HBV
  • First-in-class gene editing therapy targeting Hepatitis B
  • Potential to address a significant unmet medical need

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Apr. 15, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S.

Frequently Asked Questions

What is PBGENE-HBV?

PBGENE-HBV is a first-in-class gene editing therapy developed by Precision BioSciences to treat chronic Hepatitis B.

What does FDA Fast Track Designation mean?

FDA Fast Track Designation facilitates the development and review of drugs that address unmet medical needs.

Which platform does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for developing its gene editing therapies.

Why is PBGENE-HBV significant?

PBGENE-HBV has the potential to eliminate the root cause of chronic Hepatitis B, addressing a major health issue.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences PBGENE-HBV FDA Fast Track gene editing Hepatitis B
Last updated: Apr 15, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →